TARRYTOWN, N.Y., Oct. 4, 2022
/PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
(NASDAQ: REGN) today announced that it will report its
third quarter 2022 financial and operating results on Thursday, November 3, 2022, before the U.S.
financial markets open. The Company will host a conference call and
simultaneous webcast at 8:30 AM Eastern
Time that day.
Conference Call Information
Participants may
access the conference call live via webcast on the 'Investors and
Media' page of Regeneron's website at
https://investor.regeneron.com. To participate via telephone,
please register in advance at this link. Upon registration, all
telephone participants will receive a confirmation email detailing
how to join the conference call, including the dial-in number along
with a unique passcode and registrant ID that can be used to access
the call. A replay of the conference call and webcast will be
archived on the Company's website for at least 30 days.
About Regeneron
Regeneron (NASDAQ: REGN)
is a leading biotechnology company that invents, develops and
commercializes life-transforming medicines for people with serious
diseases. Founded and led for nearly 35 years by
physician-scientists, our unique ability to repeatedly and
consistently translate science into medicine has led to nine
FDA-approved treatments and product candidates in development,
almost all of which were homegrown in our laboratories. Our
medicines and pipeline are designed to help patients with eye
diseases, allergic and inflammatory diseases, cancer,
cardiovascular and metabolic diseases, pain, hematologic
conditions, infectious diseases and rare diseases.
Regeneron is accelerating and improving the traditional drug
development process through our proprietary VelociSuite®
technologies, such as VelocImmune®, which uses unique
genetically humanized mice to produce optimized fully human
antibodies and bispecific antibodies, and through ambitious
research initiatives such as the Regeneron Genetics Center, which
is conducting one of the largest genetics sequencing efforts in the
world.
For more information, please visit www.Regeneron.com or follow
@Regeneron on Twitter.
Contact Information:
Investor
Relations
Ryan Crowe
914.847.8790
ryan.crowe@regeneron.com
Corporate Communications
Christina Chan
914.847.8827
christina.chan@regeneron.com
View original
content:https://www.prnewswire.com/news-releases/regeneron-to-report-third-quarter-2022-financial-and-operating-results-and-host-conference-call-and-webcast-on-november-3-2022-301640263.html
SOURCE Regeneron Pharmaceuticals, Inc.